The m
Humans
RNA, Long Noncoding
/ genetics
Up-Regulation
Cell Line, Tumor
Cell Proliferation
/ genetics
MicroRNAs
/ genetics
Colorectal Neoplasms
/ pathology
Fatty Acids
Gene Expression Regulation, Neoplastic
Cell Movement
/ genetics
POU Domain Factors
/ genetics
Methyltransferases
/ metabolism
Fatty Acid Synthase, Type I
/ genetics
Colorectal cancer
Fatty acid metabolism
Growth
POU6F2-AS1
Journal
Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698
Informations de publication
Date de publication:
16 Mar 2024
16 Mar 2024
Historique:
received:
14
12
2023
accepted:
19
02
2024
medline:
18
3
2024
pubmed:
16
3
2024
entrez:
16
3
2024
Statut:
epublish
Résumé
Long noncoding RNAs (lncRNAs) have emerged as key players in tumorigenesis and tumour progression. However, the biological functions and potential mechanisms of lncRNAs in colorectal cancer (CRC) are unclear. The novel lncRNA POU6F2-AS1 was identified through bioinformatics analysis, and its expression in CRC patients was verified via qRT-PCR and FISH. In vitro and in vivo experiments, such as BODIPY staining, Oil Red O staining, triglyceride (TAG) assays, and liquid chromatography mass spectrometry (LC-MS) were subsequently performed with CRC specimens and cells to determine the clinical significance, and functional roles of POU6F2-AS1. Biotinylated RNA pull-down, RIP, Me-RIP, ChIP, and patient-derived organoid (PDO) culture assays were performed to confirm the underlying mechanism of POU6F2-AS1. The lncRNA POU6F2-AS1 is markedly upregulated in CRC and associated with adverse clinicopathological features and poor overall survival in CRC patients. Functionally, POU6F2-AS1 promotes the growth and lipogenesis of CRC cells both in vitro and in vivo. Mechanistically, METTL3-induced m Our data revealed that the upregulation of POU6F2-AS1 plays a critical role in CRC fatty acid metabolism and might provide a novel promising biomarker and therapeutic target for CRC.
Sections du résumé
BACKGROUND
BACKGROUND
Long noncoding RNAs (lncRNAs) have emerged as key players in tumorigenesis and tumour progression. However, the biological functions and potential mechanisms of lncRNAs in colorectal cancer (CRC) are unclear.
METHODS
METHODS
The novel lncRNA POU6F2-AS1 was identified through bioinformatics analysis, and its expression in CRC patients was verified via qRT-PCR and FISH. In vitro and in vivo experiments, such as BODIPY staining, Oil Red O staining, triglyceride (TAG) assays, and liquid chromatography mass spectrometry (LC-MS) were subsequently performed with CRC specimens and cells to determine the clinical significance, and functional roles of POU6F2-AS1. Biotinylated RNA pull-down, RIP, Me-RIP, ChIP, and patient-derived organoid (PDO) culture assays were performed to confirm the underlying mechanism of POU6F2-AS1.
RESULTS
RESULTS
The lncRNA POU6F2-AS1 is markedly upregulated in CRC and associated with adverse clinicopathological features and poor overall survival in CRC patients. Functionally, POU6F2-AS1 promotes the growth and lipogenesis of CRC cells both in vitro and in vivo. Mechanistically, METTL3-induced m
CONCLUSIONS
CONCLUSIONS
Our data revealed that the upregulation of POU6F2-AS1 plays a critical role in CRC fatty acid metabolism and might provide a novel promising biomarker and therapeutic target for CRC.
Identifiants
pubmed: 38491348
doi: 10.1186/s12943-024-01962-8
pii: 10.1186/s12943-024-01962-8
doi:
Substances chimiques
RNA, Long Noncoding
0
MicroRNAs
0
Fatty Acids
0
POU6F2 protein, human
0
POU Domain Factors
0
METTL3 protein, human
EC 2.1.1.62
Methyltransferases
EC 2.1.1.-
FASN protein, human
EC 2.3.1.85
Fatty Acid Synthase, Type I
EC 2.3.1.85
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
55Subventions
Organisme : National Natural Science Foundation of China
ID : 82203486
Organisme : National Natural Science Foundation of China
ID : 82073133
Organisme : Natural Science Foundation of Jiangsu Province
ID : BK20231159
Organisme : Scientific Research of Jiangsu Health Committee
ID : ZDA2020005
Organisme : Six Talents Peak' High-level Talent Project of Jiangsu Province
ID : WSW-050
Organisme : Xuzhou Medical Leading Talents Training Project
ID : XWRCHT20210034
Informations de copyright
© 2024. The Author(s).
Références
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.
pubmed: 36633525
doi: 10.3322/caac.21763
Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233–54.
pubmed: 36856579
doi: 10.3322/caac.21772
Andrei P, Battuello P, Grasso G, Rovera E, Tesio N, Bardelli A. Integrated approaches for precision oncology in colorectal cancer: the more you know, the better. Semin Cancer Biol. 2022;84:199–213.
pubmed: 33848627
doi: 10.1016/j.semcancer.2021.04.007
Guzman Y, Rios J, Paredes J, Dominguez P, Maurel J, Gonzalez-Abos C, Otero-Pineiro A, Almenara R, Ladra M, Prada B, et al. Time interval between the end of Neoadjuvant Therapy and Elective Resection of locally advanced rectal Cancer in the CRONOS Study. JAMA Surg. 2023;158:910–9.
pubmed: 37436726
doi: 10.1001/jamasurg.2023.2521
Sedlak JC, Yilmaz OH, Roper J. Metabolism and colorectal Cancer. Annu Rev Pathol. 2023;18:467–92.
pubmed: 36323004
doi: 10.1146/annurev-pathmechdis-031521-041113
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
La Vecchia S, Sebastian C. Metabolic pathways regulating colorectal cancer initiation and progression. Semin Cell Dev Biol. 2020;98:63–70.
pubmed: 31129171
doi: 10.1016/j.semcdb.2019.05.018
Chen D, Zhou X, Yan P, Yang C, Li Y, Han L, Ren X. Lipid metabolism reprogramming in colorectal cancer. J Cell Biochem. 2023;124:3–16.
pubmed: 36334309
doi: 10.1002/jcb.30347
Fhu CW, Ali A. Fatty acid synthase: an emerging target in Cancer. Molecules 2020, 25.
Wei W, Qin B, Wen W, Zhang B, Luo H, Wang Y, Xu H, Xie X, Liu S, Jiang X, et al. FBXW7beta loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth. Signal Transduct Target Ther. 2023;8:187.
pubmed: 37202390
pmcid: 10195794
doi: 10.1038/s41392-023-01405-8
Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17:47–62.
pubmed: 26666209
doi: 10.1038/nrg.2015.10
Choi SW, Kim HW, Nam JW. The small peptide world in long noncoding RNAs. Brief Bioinform. 2019;20:1853–64.
pubmed: 30010717
pmcid: 6917221
doi: 10.1093/bib/bby055
Yang Y, Yan X, Li X, Ma Y, Goel A. Long non-coding RNAs in colorectal cancer: novel oncogenic mechanisms and promising clinical applications. Cancer Lett. 2021;504:67–80.
pubmed: 33577977
pmcid: 9715275
doi: 10.1016/j.canlet.2021.01.009
Liu B, Song A, Gui P, Wang J, Pan Y, Li C, Li S, Zhang Y, Jiang T, Xu Y, et al. Long noncoding RNA LINC01594 inhibits the CELF6-mediated splicing of oncogenic CD44 variants to promote colorectal cancer metastasis. Cell Death Dis. 2023;14:427.
pubmed: 37452042
pmcid: 10349055
doi: 10.1038/s41419-023-05924-8
Yang T, Chen WC, Shi PC, Liu MR, Jiang T, Song H, Wang JQ, Fan RZ, Pei DS, Song J. Long noncoding RNA MAPKAPK5-AS1 promotes colorectal cancer progression by cis-regulating the nearby gene MK5 and acting as a let-7f-1-3p sponge. J Exp Clin Cancer Res. 2020;39:139.
pubmed: 32690100
pmcid: 7370515
doi: 10.1186/s13046-020-01633-8
Cheng Z, Wang J, Xu Y, Jiang T, Xue Z, Li S, Zhao Y, Song H, Song J. N7-methylguanosine-related lncRNAs: distinction between hot and cold tumors and construction of predictive models in colon adenocarcinoma. Front Oncol. 2022;12:951452.
pubmed: 36185235
pmcid: 9520617
doi: 10.3389/fonc.2022.951452
Wang H, Chen Y, Liu Y, Li Q, Luo J, Wang L, Chen Y, Sang C, Zhang W, Ge X, et al. The lncRNA ZFAS1 regulates lipogenesis in colorectal cancer by binding polyadenylate-binding protein 2 to stabilize SREBP1 mRNA. Mol Ther Nucleic Acids. 2022;27:363–74.
pubmed: 35036050
doi: 10.1016/j.omtn.2021.12.010
Christensen LL, True K, Hamilton MP, Nielsen MM, Damas ND, Damgaard CK, Ongen H, Dermitzakis E, Bramsen JB, Pedersen JS, et al. SNHG16 is regulated by the wnt pathway in colorectal cancer and affects genes involved in lipid metabolism. Mol Oncol. 2016;10:1266–82.
pubmed: 27396952
pmcid: 5423192
doi: 10.1016/j.molonc.2016.06.003
Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond). 2018;38:27.
pubmed: 29784041
Rohrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16:732–49.
pubmed: 27658529
doi: 10.1038/nrc.2016.89
Cao D, Yang J, Deng Y, Su M, Wang Y, Feng X, Xiong Y, Bai E, Duan Y, Huang Y. Discovery of a mammalian FASN inhibitor against xenografts of non-small cell lung cancer and melanoma. Signal Transduct Target Ther. 2022;7:273.
pubmed: 36002450
pmcid: 9402528
doi: 10.1038/s41392-022-01099-4
Yao ZT, Yang YM, Sun MM, He Y, Liao L, Chen KS, Li B. New insights into the interplay between long non-coding RNAs and RNA-binding proteins in cancer. Cancer Commun (Lond). 2022;42:117–40.
pubmed: 35019235
doi: 10.1002/cac2.12254
Xia A, Yuan W, Wang Q, Xu J, Gu Y, Zhang L, Chen C, Wang Z, Wu D, He Q, et al. The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription. Nat Cancer. 2022;3:203–18.
pubmed: 35122073
doi: 10.1038/s43018-021-00315-4
Ren L, Fang X, Shrestha SM, Ji Q, Ye H, Liang Y, Liu Y, Feng Y, Dong J, Shi R. LncRNA SNHG16 promotes development of oesophageal squamous cell carcinoma by interacting with EIF4A3 and modulating RhoU mRNA stability. Cell Mol Biol Lett. 2022;27:89.
pubmed: 36221055
pmcid: 9552503
doi: 10.1186/s11658-022-00386-w
Kuwano M, Shibata T, Watari K, Ono M. Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. Cancer Sci. 2019;110:1536–43.
pubmed: 30903644
pmcid: 6500994
doi: 10.1111/cas.14006
Wu QN, Luo XJ, Liu J, Lu YX, Wang Y, Qi J, Liu ZX, Huang QT, Liu ZK, Lu JB, et al. MYC-Activated LncRNA MNX1-AS1 promotes the progression of Colorectal Cancer by stabilizing YB1. Cancer Res. 2021;81:2636–50.
pubmed: 33782099
doi: 10.1158/0008-5472.CAN-20-3747
Chen S, Li K, Guo J, Chen HN, Ming Y, Jin Y, Xu F, Zhang T, Yang Y, Ye Z, et al. circNEIL3 inhibits tumor metastasis through recruiting the E3 ubiquitin ligase Nedd4L to degrade YBX1. Proc Natl Acad Sci U S A. 2023;120:e2215132120.
pubmed: 36961927
pmcid: 10068820
doi: 10.1073/pnas.2215132120
Kim A, Shim S, Kim YH, Kim MJ, Park S, Myung JK. Inhibition of Y Box binding protein 1 suppresses cell growth and motility in Colorectal Cancer. Mol Cancer Ther. 2020;19:479–89.
pubmed: 31672764
doi: 10.1158/1535-7163.MCT-19-0265
Lyabin DN, Eliseeva IA, Ovchinnikov LP. YB-1 protein: functions and regulation. Wiley Interdiscip Rev RNA. 2014;5:95–110.
pubmed: 24217978
doi: 10.1002/wrna.1200
Li H, Chen Z, Zhang Y, Yuan P, Liu J, Ding L, Ye Q. MiR-4310 regulates hepatocellular carcinoma growth and metastasis through lipid synthesis. Cancer Lett. 2021;519:161–71.
pubmed: 34303763
doi: 10.1016/j.canlet.2021.07.029
Hu N, Li Y, Zhao Y, Wang Q, You JC, Zhang XD, Ye LH. A novel positive feedback loop involving FASN/p-ERK1/2/5-LOX/LTB4/FASN sustains high growth of breast cancer cells. Acta Pharmacol Sin. 2011;32:921–9.
pubmed: 21643005
pmcid: 4003129
doi: 10.1038/aps.2011.40
Wang JZ, Zhu H, You P, Liu H, Wang WK, Fan X, Yang Y, Xu K, Zhu Y, Li Q et al. Upregulated YB-1 protein promotes glioblastoma growth through a YB-1/CCT4/mLST8/mTOR pathway. J Clin Invest 2022, 132.
Zhang Y, Huang YX, Wang DL, Yang B, Yan HY, Lin LH, Li Y, Chen J, Xie LM, Huang YS, et al. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network. Theranostics. 2020;10:10823–37.
pubmed: 32929382
pmcid: 7482804
doi: 10.7150/thno.47830
Chen Q, Wang H, Li Z, Li F, Liang L, Zou Y, Shen H, Li J, Xia Y, Cheng Z, et al. Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription. J Hepatol. 2022;76:135–47.
pubmed: 34509526
doi: 10.1016/j.jhep.2021.08.027
Su H, Fan G, Huang J, Qiu X. LncRNA HOXC-AS3 promotes non-small-cell lung cancer growth and metastasis through upregulation of YBX1. Cell Death Dis. 2022;13:307.
pubmed: 35387975
pmcid: 8986809
doi: 10.1038/s41419-022-04723-x
Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer. 2009;100:1369–72.
pubmed: 19352381
pmcid: 2694429
doi: 10.1038/sj.bjc.6605007
Liu HT, Zou YX, Zhu WJ, Sen L, Zhang GH, Ma RR, Guo XY, Gao P. lncRNA THAP7-AS1, transcriptionally activated by SP1 and post-transcriptionally stabilized by METTL3-mediated m6A modification, exerts oncogenic properties by improving CUL4B entry into the nucleus. Cell Death Differ. 2022;29:627–41.
pubmed: 34608273
doi: 10.1038/s41418-021-00879-9
Xie J, Zhang H, Wang K, Ni J, Ma X, Khoury CJ, Prifti V, Hoard B, Cerenzia EG, Yin L, et al. M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2 transcription. Oncogene. 2023;42:2956–70.
pubmed: 37612524
pmcid: 10541332
doi: 10.1038/s41388-023-02814-3
Zhu TY, Hong LL, Ling ZQ. Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential. Biomark Res. 2023;11:62.
pubmed: 37280679
pmcid: 10245617
doi: 10.1186/s40364-023-00499-0
Mattick JS, Rinn JL. Discovery and annotation of long noncoding RNAs. Nat Struct Mol Biol. 2015;22:5–7.
pubmed: 25565026
doi: 10.1038/nsmb.2942
Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ. Targeting noncoding RNAs in disease. J Clin Invest. 2017;127:761–71.
pubmed: 28248199
pmcid: 5330746
doi: 10.1172/JCI84424
Wu XY, Xie Y, Zhou LY, Zhao YY, Zhang J, Zhang XF, Guo S, Yu XY. Long noncoding RNA POU6F2-AS1 regulates lung cancer aggressiveness through sponging miR-34c-5p to modulate KCNJ4 expression. Genet Mol Biol. 2021;44:e20200050.
pubmed: 33999092
pmcid: 8127722
doi: 10.1590/1678-4685-gmb-2020-0050
Lu D, Chen A. lncRNA POU6F2-AS1 regulated by KIAA1429 contributes to Colorectal Cancer Progression in an m(6)a modification manner. Mol Biotechnol 2023.
Tang Z, Xu Z, Zhu X, Zhang J. New insights into molecules and pathways of cancer metabolism and therapeutic implications. Cancer Commun (Lond). 2021;41:16–36.
pubmed: 33174400
doi: 10.1002/cac2.12112
Broadfield LA, Pane AA, Talebi A, Swinnen JV, Fendt SM. Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev Cell. 2021;56:1363–93.
pubmed: 33945792
doi: 10.1016/j.devcel.2021.04.013
Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4–22.
pubmed: 31819192
doi: 10.1038/s41416-019-0650-z
Zhang J, Song Y, Shi Q, Fu L. Research progress on FASN and MGLL in the regulation of abnormal lipid metabolism and the relationship between tumor invasion and metastasis. Front Med. 2021;15:649–56.
pubmed: 33973101
doi: 10.1007/s11684-021-0830-0
Guo Z, Huo X, Li X, Jiang C, Xue L. Advances in regulation and function of stearoyl-CoA desaturase 1 in cancer, from bench to bed. Sci China Life Sci 2023.
Icard P, Wu Z, Fournel L, Coquerel A, Lincet H, Alifano M. ATP citrate lyase: a central metabolic enzyme in cancer. Cancer Lett. 2020;471:125–34.
pubmed: 31830561
doi: 10.1016/j.canlet.2019.12.010
Mounier C, Bouraoui L, Rassart E. Lipogenesis in cancer progression (review). Int J Oncol. 2014;45:485–92.
pubmed: 24827738
doi: 10.3892/ijo.2014.2441
Ecker J, Benedetti E, Kindt ASD, Horing M, Perl M, Machmuller AC, Sichler A, Plagge J, Wang Y, Zeissig S, et al. The Colorectal Cancer Lipidome: identification of a robust tumor-specific lipid species signature. Gastroenterology. 2021;161:910–923e919.
pubmed: 34000281
doi: 10.1053/j.gastro.2021.05.009
Zheng ZQ, Li ZX, Guan JL, Liu X, Li JY, Chen Y, Lin L, Kou J, Lv JW, Zhang LL, et al. Long noncoding RNA TINCR-Mediated regulation of Acetyl-CoA metabolism promotes nasopharyngeal carcinoma progression and Chemoresistance. Cancer Res. 2020;80:5174–88.
pubmed: 33067266
doi: 10.1158/0008-5472.CAN-19-3626
Jia Y, Yan Q, Zheng Y, Li L, Zhang B, Chang Z, Wang Z, Tang H, Qin Y, Guan XY. Long non-coding RNA NEAT1 mediated RPRD1B stability facilitates fatty acid metabolism and lymph node metastasis via c-Jun/c-Fos/SREBP1 axis in gastric cancer. J Exp Clin Cancer Res. 2022;41:287.
pubmed: 36171622
pmcid: 9520879
doi: 10.1186/s13046-022-02449-4
Peng JY, Cai DK, Zeng RL, Zhang CY, Li GC, Chen SF, Yuan XQ, Peng L. Upregulation of Superenhancer-Driven LncRNA FASRL by USF1 promotes De Novo fatty acid biosynthesis to Exacerbate Hepatocellular Carcinoma. Adv Sci (Weinh). 2022;10:e2204711.
pubmed: 36307901
doi: 10.1002/advs.202204711
Menendez JA, Lupu R. Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opin Ther Targets. 2017;21:1001–16.
pubmed: 28922023
doi: 10.1080/14728222.2017.1381087
Ferre F, Colantoni A, Helmer-Citterich M. Revealing protein-lncRNA interaction. Brief Bioinform. 2016;17:106–16.
pubmed: 26041786
doi: 10.1093/bib/bbv031
Zhou Y, Shao Y, Hu W, Zhang J, Shi Y, Kong X, Jiang J. A novel long noncoding RNA SP100-AS1 induces radioresistance of colorectal cancer via sponging miR-622 and stabilizing ATG3. Cell Death Differ. 2023;30:111–24.
pubmed: 35978049
doi: 10.1038/s41418-022-01049-1
Gandhi M, Gross M, Holler JM, Coggins SA, Patil N, Leupold JH, Munschauer M, Schenone M, Hartigan CR, Allgayer H, et al. The lncRNA lincNMR regulates nucleotide metabolism via a YBX1 - RRM2 axis in cancer. Nat Commun. 2020;11:3214.
pubmed: 32587247
pmcid: 7316977
doi: 10.1038/s41467-020-17007-9
Wang Y, Feng YC, Gan Y, Teng L, Wang L, La T, Wang P, Gu Y, Yan L, Li N, et al. LncRNA MILIP links YBX1 to translational activation of Snai1 and promotes metastasis in clear cell renal cell carcinoma. J Exp Clin Cancer Res. 2022;41:260.
pubmed: 36028903
pmcid: 9414127
doi: 10.1186/s13046-022-02452-9
Yin H, Chen L, Piao S, Wang Y, Li Z, Lin Y, Tang X, Zhang H, Zhang H, Wang X. M6A RNA methylation-mediated RMRP stability renders proliferation and progression of non-small cell lung cancer through regulating TGFBR1/SMAD2/SMAD3 pathway. Cell Death Differ. 2023;30:605–17.
pubmed: 34628486
doi: 10.1038/s41418-021-00888-8
Li Y, Gao Y, Niu X, Tang M, Li J, Song B, Guan X. LncRNA BASP1-AS1 interacts with YBX1 to regulate notch transcription and drives the malignancy of melanoma. Cancer Sci. 2021;112:4526–42.
pubmed: 34533860
pmcid: 8586662
doi: 10.1111/cas.15140
Zhang H, Yu H, Ren D, Sun Y, Guo F, Cai H, Zhou C, Zhou Y, Jin X, Wu H. CBX3 regulated by YBX1 promotes smoking-induced pancreatic Cancer progression via inhibiting SMURF2 expression. Int J Biol Sci. 2022;18:3484–97.
pubmed: 35637952
pmcid: 9134897
doi: 10.7150/ijbs.68995
Lu X, Wang J, Wang W, Lu C, Qu T, He X, Liu X, Guo R, Zhang E. Copy number amplification and SP1-activated lncRNA MELTF-AS1 regulates tumorigenesis by driving phase separation of YBX1 to activate ANXA8 in non-small cell lung cancer. Oncogene. 2022;41:3222–38.
pubmed: 35508543
doi: 10.1038/s41388-022-02292-z
Mordovkina D, Lyabin DN, Smolin EA, Sogorina EM, Ovchinnikov LP, Eliseeva I. Y-Box binding proteins in mRNP Assembly, translation, and Stability Control. Biomolecules 2020, 10.
Wang Z, Zhou J, Zhang H, Ge L, Li J, Wang H: RNA m(6) A methylation in cancer. Mol Oncol 2023;17:195–229.
Fu Y, Dominissini D, Rechavi G, He C. Gene expression regulation mediated through reversible m(6)a RNA methylation. Nat Rev Genet. 2014;15:293–306.
pubmed: 24662220
doi: 10.1038/nrg3724
Chen L, Zhang C, Ma W, Huang J, Zhao Y, Liu H. METTL3-mediated m6A modification stabilizes TERRA and maintains telomere stability. Nucleic Acids Res. 2022;50:11619–34.
pubmed: 36399511
pmcid: 9723618
doi: 10.1093/nar/gkac1027
Yao B, Zhang Q, Yang Z, An F, Nie H, Wang H, Yang C, Sun J, Chen K, Zhou J, et al. CircEZH2/miR-133b/IGF2BP2 aggravates colorectal cancer progression via enhancing the stability of m(6)A-modified CREB1 mRNA. Mol Cancer. 2022;21:140.
pubmed: 35773744
pmcid: 9245290
doi: 10.1186/s12943-022-01608-7
Hou P, Meng S, Li M, Lin T, Chu S, Li Z, Zheng J, Gu Y, Bai J. LINC00460/DHX9/IGF2BP2 complex promotes colorectal cancer proliferation and metastasis by mediating HMGA1 mRNA stability depending on m6A modification. J Exp Clin Cancer Res. 2021;40:52.
pubmed: 33526059
pmcid: 7851923
doi: 10.1186/s13046-021-01857-2
Huizhe, Wu Xiangyu, Ding Xiaoyun, Hu Qing, Zhao Qiuchen, Chen Tong, Sun Yalun, Li Hao, Guo Meng, Li Ziming, Gao Weifan, Yao Lin, Zhao Kai, Li Minjie, Wei (2022) LINC01021 maintains tumorigenicity by enhancing N6-methyladenosine reader IMP2 dependent stabilization of MSX1 and JARID2: implication in colorectal cancer. Oncogene. 2022;41(13):1959–1973. https://doi.org/10.1038/s41388-022-02189-x